{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T19:37:34Z","timestamp":1776713854177,"version":"3.51.2"},"reference-count":103,"publisher":"FapUNIFESP (SciELO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. bras. pneumol."],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:p>Malignant mesothelioma (MM) is a highly aggressive form of cancer, has a long latency period, and is resistant to chemotherapy. It is extremely fatal, with a mean survival of less than one year. The development of MM is strongly correlated with exposure to asbestos and with other factors, such as erionite and simian virus 40. Although various countries have banned the use of asbestos, MM has proven to be difficult to control and there appears to be a trend toward an increase in its incidence in the years to come. In Brazil, MM has not been widely studied from a genetic or biochemical standpoint. In addition, there have been few epidemiological studies of the disease, and the profile of its incidence has yet to be well established in the Brazilian population. The objective of this study was to review the literature regarding the processes of malignant transformation, as well as the respective mechanisms of tumorigenesis, in MM.<\/jats:p>","DOI":"10.1590\/s1806-37132014000400012","type":"journal-article","created":{"date-parts":[[2014,9,8]],"date-time":"2014-09-08T12:29:54Z","timestamp":1410179394000},"page":"429-442","source":"Crossref","is-referenced-by-count":7,"title":["Overview of the biochemical and genetic processes in malignant mesothelioma"],"prefix":"10.1590","volume":"40","author":[{"given":"Leonardo Vin\u00edcius Monteiro de","family":"Assis","sequence":"first","affiliation":[{"name":"University of S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro C\u00e9sar","family":"Isoldi","sequence":"additional","affiliation":[{"name":"Federal University of Ouro Preto, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"2-3","key":"ref1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","article-title":"Mesothelioma epidemiology, carcinogenesis, and pathogenesis","volume":"9","author":"Yang H","year":"2008","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone M","year":"2012","journal-title":"J Cell Physiol"},{"issue":"4","key":"ref3","first-page":"356","article-title":"Asbestos-related diseases of the lungs and pleura: uses, trends and management over the last century","volume":"11","author":"Becklake MR","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"issue":"28","key":"ref4","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"van Meerbeeck JP","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref5","first-page":"32","article-title":"Peritoneal mesothelioma: a review","volume":"9","author":"Bridda A","year":"2007","journal-title":"MedGenMed"},{"key":"ref6","article-title":"Current Trends in the Management of Malignant Peritoneal Mesothelioma","author":"Miura JT","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1258\/jrsm.98.10.455","article-title":"Mesothelioma: time to take stock","volume":"98","author":"Tan C","year":"2005","journal-title":"J R Soc Med"},{"issue":"6","key":"ref8","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"van Zandwijk N","year":"2013","journal-title":"J Thorac Dis"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure T","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref10","first-page":"S238","article-title":"Management of malignant pleural mesothelioma-The European experience","volume":"6","author":"Opitz I","year":"2014","journal-title":"J Thorac Dis"},{"issue":"14","key":"ref11","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang NJ","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1476-5381.2012.01873.x","article-title":"Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma","volume":"166","author":"Favoni RE","year":"2012","journal-title":"Br J Pharmacol"},{"key":"ref13","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner JC","year":"1960","journal-title":"Br J Ind Med"},{"issue":"27","key":"ref14","doi-asserted-by":"crossref","first-page":"10397","DOI":"10.1073\/pnas.0604008103","article-title":"TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis","volume":"103","author":"Yang H","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","article-title":"Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma","volume":"18","author":"Carbone M","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1289\/ehp.021101003","article-title":"Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species","volume":"110","author":"Xu A","year":"2002","journal-title":"Environ Health Perspect"},{"issue":"9","key":"ref17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3109\/08958378.2013.807321","article-title":"The role of genotoxicity in asbestos-induced mesothelioma: an explanation for the differences in carcinogenic potential among fiber types","volume":"25","author":"Barlow CA","year":"2013","journal-title":"Inhal Toxicol"},{"issue":"C","key":"ref18","first-page":"11","article-title":"Arsenic, metals, fibres, and dusts","volume":"100","year":"2012","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone M","year":"2012","journal-title":"J Transl Med"},{"issue":"33","key":"ref20","doi-asserted-by":"crossref","first-page":"13618","DOI":"10.1073\/pnas.1105887108","article-title":"Erionite exposure in North Dakota and Turkish villages with mesothelioma","volume":"108","author":"Carbone M","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"ref21","first-page":"232","article-title":"The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma","volume":"1845","author":"de Assis LV","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"ref22","series-title":"[homepage on the Internet]","year":"2014"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1179\/oeh.2008.14.3.170","article-title":"Mesothelioma mortality in Brazil, 1980-2003","volume":"14","author":"Pedra F","year":"2008","journal-title":"Int J Occup Environ Health"},{"key":"ref24","series-title":"[homepage on the Internet]","year":"2013"},{"key":"ref25","first-page":"S99","article-title":"Histopathological diagnosis of pneumoconiosis [Article in Portuguese]","volume":"32","author":"Capelozzi VL","year":"2006","journal-title":"J Bras Pneumol"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1590\/S0100-879X2003001000010","article-title":"Identification of rounded atelectasis in workers exposed to asbestos by contrast helical computed tomography","volume":"36","author":"Terra-Filho M","year":"2003","journal-title":"Braz J Med Biol Res"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1590\/S1806-37132006001100011","article-title":"Morphological aspects as prognostic factors in malignant mesothelioma: a study of 58 cases","volume":"32","author":"Motta AB","year":"2006","journal-title":"J Bras Pneumol"},{"key":"ref28","series-title":"Lei no 9.055, de 1 de Junho de 1995. Disciplina a extra\u00e7\u00e3o, industrializa\u00e7\u00e3o, utiliza\u00e7\u00e3o, comercializa\u00e7\u00e3o e transporte do asbesto\/amianto e dos produtos que o contenham, bem como das fibras naturais e artificiais, de qualquer origem, utilizadas para o mesmo fim e d\u00e1 outras provid\u00eancias","year":"1995"},{"issue":"3","key":"ref29","first-page":"265","article-title":"Malignant mesothelioma of the pleura with etiological association to asbestos: report of 3 clinical cases [Article in Portuguese]. Rev Assoc Med","volume":"43","author":"de Capitani EM","year":"1997","journal-title":"Bras"},{"issue":"1","key":"ref30","first-page":"37","article-title":"Well-differentiated papillary mesothelioma of the peritoneum: case report and literature review [Article in Portuguese]. J Bras Patol Med","volume":"41","author":"Almeida DB","year":"2005","journal-title":"Lab"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5271\/sjweh.288","article-title":"Occupational risk factors of lung cancer in S\u00e3o Paulo, Brazil","volume":"24","author":"Wunsch-Filho V","year":"1998","journal-title":"Scand J Work Environ Health"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/oem.2004.016188","article-title":"Non-malignant consequences of decreasing asbestos exposure in the Brazil chrysotile mines and mills","volume":"62","author":"Bagatin E","year":"2005","journal-title":"Occup Environ Med"},{"key":"ref33","article-title":"Mortality from pleural mesothelioma in Rio de","author":"Pinheiro GA","year":"2000","journal-title":"Janeiro, Brazil, 1979-"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s13277-013-1210-4","article-title":"The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms","volume":"35","author":"de Assis LV","year":"2014","journal-title":"Tumour Biol"},{"issue":"2","key":"ref35","first-page":"F115","article-title":"The p16INK4a\/CDKN2A tumor suppressor and its relatives","volume":"1378","author":"Ruas M","year":"1998","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"ref36","doi-asserted-by":"crossref","first-page":"632","DOI":"10.5858\/arpa.2012-0108-OA","article-title":"Dacic S p16 Deletion in sarcomatoid tumors of the lung and pleura","volume":"137","author":"Tochigi N","year":"2013","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/jclinpath-2011-200208","article-title":"Genomic gains and losses in malignant mesothelioma demonstrated by FISH analysis of paraffin-embedded tissues","volume":"65","author":"Takeda M","year":"2012","journal-title":"J Clin Pathol"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1349-7006.2006.00386.x","article-title":"Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32","volume":"98","author":"Taniguchi T","year":"2007","journal-title":"Cancer Sci"},{"issue":"24","key":"ref39","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","article-title":"High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas","volume":"92","author":"Bianchi AB","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ref40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M","article-title":"Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation","volume":"24","author":"Cheng JQ","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/mutage\/get008","article-title":"Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma","volume":"28","author":"Andujar P","year":"2013","journal-title":"Mutagenesis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4137\/CMO.S15239","article-title":"The Importance of Multidisciplinary Approach in Early Detection of BAP1 Tumor Predisposition Syndrome: Clinical Management and Risk Assessment","volume":"8","author":"Battaglia A","year":"2014","journal-title":"Clin Med Insights Oncol"},{"issue":"5","key":"ref43","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.cancergen.2013.05.018","article-title":"Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma","volume":"206","author":"Cheung M","year":"2013","journal-title":"Cancer Genet"},{"issue":"7","key":"ref44","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21: 1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott M","year":"2011","journal-title":"Nat Genet"},{"issue":"11","key":"ref45","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/JTO.0b013e31829e7ef9","article-title":"Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations","volume":"8","author":"Zauderer MG","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"6810","key":"ref46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein B","year":"2000","journal-title":"Nature"},{"issue":"10","key":"ref47","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrc2730","article-title":"The expanding universe of p53 targets","volume":"9","author":"Menendez D","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"6333","key":"ref48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/352345a0","article-title":"Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6","volume":"352","author":"Yonish-Rouach E","year":"1991","journal-title":"Nature"},{"issue":"7128","key":"ref49","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05541","article-title":"Restoration of p53 function leads to tumour regression in vivo","volume":"445","author":"Ventura A","year":"2007","journal-title":"Nature"},{"issue":"7","key":"ref50","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido Y","year":"2013","journal-title":"Carcinogenesis"},{"issue":"2","key":"ref51","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H","article-title":"Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma","volume":"180","author":"Murthy SS","year":"1999","journal-title":"J Cell Physiol"},{"issue":"7359","key":"ref52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nature10275","article-title":"A continuum model for tumour suppression","volume":"476","author":"Berger AH","year":"2011","journal-title":"Nature"},{"issue":"9","key":"ref53","first-page":"2610","article-title":"p53 and Kirsten-ras mutations in human mesothelioma cell lines.","volume":"52","author":"Metcalf RA","year":"1992","journal-title":"Cancer Res"},{"issue":"4","key":"ref54","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2559.1992.tb00403.x","article-title":"p53 expression is common in malignant mesothelioma","volume":"21","author":"Kafiri G","year":"1992","journal-title":"Histopathology"},{"issue":"4","key":"ref55","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng0497-356","article-title":"Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers","volume":"15","author":"Steck PA","year":"1997","journal-title":"Nat Genet"},{"issue":"5308","key":"ref56","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","article-title":"PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer","volume":"275","author":"Li J","year":"1997","journal-title":"Science"},{"issue":"5","key":"ref57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3330","article-title":"The functions and regulation of the PTEN tumour suppressor","volume":"13","author":"Song MS","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"ref58","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1158\/0008-5472.CAN-10-2488","article-title":"PTEN level in tumor suppression: how much is too little?","volume":"71","author":"Carracedo A","year":"2011","journal-title":"Cancer Res"},{"issue":"3","key":"ref59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cell.2008.04.013","article-title":"Tenets of PTEN tumor suppression","volume":"133","author":"Salmena L","year":"2008","journal-title":"Cell"},{"issue":"24","key":"ref60","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1242\/jcs.000133","article-title":"Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression","volume":"119","author":"Lindsay Y","year":"2006","journal-title":"J Cell Sci"},{"issue":"4","key":"ref61","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.molcel.2006.06.028","article-title":"Mechanistic insights into maintenance of high p53 acetylation by PTEN","volume":"23","author":"Li AG","year":"2006","journal-title":"Mol Cell"},{"issue":"9","key":"ref62","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0968-0004(02)02166-7","article-title":"The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network","volume":"27","author":"Mayo LD","year":"2002","journal-title":"Trends Biochem Sci"},{"issue":"7","key":"ref63","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1074\/jbc.M108302200","article-title":"PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy","volume":"277","author":"Mayo LD","year":"2002","journal-title":"J Biol Chem"},{"issue":"40","key":"ref64","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","article-title":"Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth","volume":"24","author":"Altomare DA","year":"2005","journal-title":"Oncogene"},{"issue":"2","key":"ref65","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s13277-012-0615-9","article-title":"PTEN protein expression in malignant pleural mesothelioma","volume":"34","author":"Agarwal V","year":"2013","journal-title":"Tumour Biol"},{"issue":"3","key":"ref66","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejcts.2007.09.045","article-title":"PTEN expression is a strong predictor of survival in mesothelioma patients","volume":"33","author":"Opitz I","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"issue":"21","key":"ref67","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0960-9822(07)00488-5","article-title":"High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice","volume":"8","author":"Suzuki A","year":"1998","journal-title":"Curr Biol"},{"issue":"1","key":"ref68","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-08-2586","article-title":"Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome","volume":"69","author":"Christensen BC","year":"2009","journal-title":"Cancer Res"},{"issue":"23","key":"ref69","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1158\/0008-5472.CAN-09-1595","article-title":"Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma","volume":"69","author":"Goto Y","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"ref70","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.molonc.2012.09.006","article-title":"MicroRNA and cancer","volume":"6","author":"Jansson MD","year":"2012","journal-title":"Mol Oncol"},{"issue":"7","key":"ref71","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/gcc.20669","article-title":"CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis","volume":"48","author":"Guled M","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"ref72","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1165\/rcmb.2009-0060OC","article-title":"MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications","volume":"42","author":"Busacca S","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"12","key":"ref73","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid G","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"ref74","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","article-title":"Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy","volume":"6","author":"Brevet M","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"3","key":"ref75","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.lungcan.2006.08.012","article-title":"EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma","volume":"54","author":"Edwards JG","year":"2006","journal-title":"Lung Cancer"},{"issue":"5","key":"ref76","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1378\/chest.128.5.3382","article-title":"Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma","volume":"128","author":"Demirag F","year":"2005","journal-title":"Chest"},{"issue":"8","key":"ref77","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/cncr.22552","article-title":"Update on the molecular biology of malignant mesothelioma","volume":"109","author":"Lee AY","year":"2007","journal-title":"Cancer"},{"issue":"23","key":"ref78","first-page":"5334","article-title":"Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor","volume":"56","author":"Zanella CL","year":"1996","journal-title":"Cancer Res"},{"issue":"5","key":"ref79","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/ijc.25763","article-title":"ERK2 is essential for the growth of human epithelioid malignant mesotheliomas","volume":"129","author":"Shukla A","year":"2011","journal-title":"Int J Cancer"},{"issue":"5","key":"ref80","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1158\/1535-7163.MCT-04-0243","article-title":"Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase\/AKT activity that predict the efficacy of Onconase","volume":"4","author":"Ramos-Nino ME","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"ref81","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/carcin\/bgp258","article-title":"Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk","volume":"30","author":"Chen M","year":"2009","journal-title":"Carcinogenesis"},{"issue":"10","key":"ref82","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/labinvest.2010.133","article-title":"Expanding therapeutic targets in bladder cancer: the PI3K\/Akt\/mTOR pathway","volume":"90","author":"Ching CB","year":"2010","journal-title":"Lab Invest"},{"issue":"2","key":"ref83","first-page":"181","article-title":"Activation of the PI3K-AKT pathway in human malignant mesothelioma cells","volume":"2","author":"Suzuki Y","year":"2009","journal-title":"Mol Med Rep"},{"issue":"6","key":"ref84","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1165\/rcmb.2004-0355OC","article-title":"A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance","volume":"33","author":"Kim KU","year":"2005","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"12","key":"ref85","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-09-3004","article-title":"Inhibition of the PI3K pathway: hope we can believe in?","volume":"16","author":"van der Heijden MS","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref86","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.136","article-title":"Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation","volume":"5","author":"Cioce M","year":"2014","journal-title":"Cell Death Dis"},{"issue":"8","key":"ref87","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey JA","year":"2007","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"ref88","first-page":"103","article-title":"Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy Expert Opin Ther","volume":"16","author":"Santarpia L","year":"2012","journal-title":"Targets"},{"issue":"8","key":"ref89","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1369\/jhc.5A6807.2006","article-title":"Phosphorylated extracellular signal-regulated kinases are significantly increased in malignant mesothelioma","volume":"54","author":"de Melo M","year":"2006","journal-title":"J Histochem Cytochem"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-3-642-10862-4_9","article-title":"Genetics and molecular biology of mesothelioma","volume":"189","author":"Fennell DA","year":"2011","journal-title":"Recent Results Cancer Res"},{"issue":"6","key":"ref91","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1470-2045(04)01492-5","article-title":"Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development","volume":"5","author":"Fennell DA","year":"2004","journal-title":"Lancet Oncol"},{"issue":"11","key":"ref92","first-page":"3508","article-title":"Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma","volume":"5","author":"Soini Y","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"11","key":"ref93","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nrc1736","article-title":"Promoting apoptosis as a strategy for cancer drug discovery","volume":"5","author":"Fesik SW","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"ref94","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1101\/gad.210773.112","article-title":"The Hippo pathway: regulators and regulations","volume":"27","author":"Yu FX","year":"2013","journal-title":"Genes Dev"},{"issue":"3","key":"ref95","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","article-title":"LATS2 is a tumor suppressor gene of malignant mesothelioma","volume":"71","author":"Murakami H","year":"2011","journal-title":"Cancer Res"},{"issue":"5","key":"ref96","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrc2389","article-title":"Wnt signalling and its impact on development and cancer","volume":"8","author":"Klaus A","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"ref97","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/beta-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"MacDonald BT","year":"2009","journal-title":"Dev Cell"},{"issue":"15","key":"ref98","first-page":"4547","article-title":"Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin","volume":"63","author":"Uematsu K","year":"2003","journal-title":"Cancer Res"},{"issue":"39","key":"ref99","doi-asserted-by":"crossref","first-page":"6672","DOI":"10.1038\/sj.onc.1207881","article-title":"Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma","volume":"23","author":"Lee AY","year":"2004","journal-title":"Oncogene"},{"issue":"6","key":"ref100","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3892\/etm.2012.511","article-title":"Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients","volume":"3","author":"Kobayashi M","year":"2012","journal-title":"Exp Ther Med"},{"issue":"7471","key":"ref101","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth C","year":"2013","journal-title":"Nature"},{"issue":"2","key":"ref102","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molonc.2012.01.011","article-title":"The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities","volume":"6","author":"De Palma M","year":"2012","journal-title":"Mol Oncol"},{"issue":"1","key":"ref103","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger UM","year":"2013","journal-title":"Pharmacol Ther"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/jbpneu\/v40n4\/1806-3713-jbpneu-40-04-00429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T15:44:10Z","timestamp":1565797450000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1806-37132014000400429&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1806-37132014000400429"],"URL":"https:\/\/doi.org\/10.1590\/s1806-37132014000400012","relation":{},"ISSN":["1806-3713"],"issn-type":[{"value":"1806-3713","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}